BioprintingCellular AgricultureMedical AM

Carcinotech raises $5.3 million to 3D print personalized tumors

The company's Carcino3D technology enables the manufacturing of 3D printed micro-tumors using cells derived from patient biopsies and blood samples to precisely simulate the tumor microenvironment

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Carcinotech, a MedTech company that 3D prints living tumors, has raised $5.3 million in funding to increase its traction in the UK and Europe, with a US expansion planned later this year. Carcinotech’s Carcino3D technology enables the manufacturing of 3D printed micro-tumors using cells derived from patient biopsies and blood samples to precisely simulate the tumor microenvironment – accelerating ethical drug screening and the delivery of more effective cancer treatments to market.

St Andrews-based Eos Advisory (Eos) led the investment alongside the Investment Fund for Scotland (IFS), managed by Maven Capital Partners, Scottish Enterprise, Old College Capital, Investing Women Angels, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment Syndicate, and Alba Equity.

“Our vision is to be at the forefront of cancer drug testing and provide personalized medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development,” said Ishani Malhotra, CEO and Founder of Carcinotech. “As part of ongoing commercialization, we have built strong industry partnerships in Europe, and are now actively engaged in replicating these in North America.”

Carcinotech raises $5.3 million to 3D print tumors. The company's Carcino3D technology enables the manufacturing of 3D printed micro-tumors.

Late last year, Carcinotech entered a partnership with CELLINK – leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing bioprinted living tumors to develop cutting-edge cancer models.

Carcinotech has also strengthened its board, chaired by industry veteran Albert Nicholl, and has launched a scientific advisory board with world-renowned oncology leaders.

According to the company, globally, an estimated 19.3 million cancer cases occurred in 2020 alone, with a fatality rate of almost 10 million cancer deaths, with breast (11.7%), lung (11.4%), colorectal (10%), and prostate (7.3%) being the most fatal. While cancer continues to affect millions, there are still a limited number of effective therapies available, and those that are available have a high degree of variation from patient to patient.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.